{"id":"dalbavancin","rwe":[{"pmid":"41892415","year":"2026","title":"Proactive Therapeutic Drug Monitoring of Dalbavancin in the Long-Term Treatment of Chronic Infections: A Narrative Review.","finding":"","journal":"Antibiotics (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41839500","year":"2026","title":"Dalbavancin.","finding":"","journal":"CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne","studyType":"Clinical Study"},{"pmid":"41832131","year":"2026","title":"[Persistent headache after dalbavancine infusion: About one case].","finding":"","journal":"Therapie","studyType":"Clinical Study"},{"pmid":"41822371","year":"2026","title":"Emergence of Dalbavancin, Vancomycin, and Daptomycin Cross-resistance in MRSA During Long-term LVAD Suppression With Vancomycin Followed by Dalbavancin: Genomic Insights and Synergy With Cefadroxil.","finding":"","journal":"Open forum infectious diseases","studyType":"Clinical Study"},{"pmid":"41820727","year":"2026","title":"Corallopyronin A exhibits potent activity against staphylococci including MRSA and isolates from prosthetic infections.","finding":"","journal":"Infection","studyType":"Clinical Study"}],"_fda":{"id":"7fddacee-2401-4514-acf0-3847da11c6e5","set_id":"1f4a5924-96d7-445a-b75f-2c0e1ffd2dea","openfda":{"unii":["33WDQ7T81E"],"route":["INTRAVENOUS"],"rxcui":["1539243"],"spl_id":["7fddacee-2401-4514-acf0-3847da11c6e5"],"brand_name":["Dalbavancin"],"spl_set_id":["1f4a5924-96d7-445a-b75f-2c0e1ffd2dea"],"package_ndc":["0480-3325-01"],"product_ndc":["0480-3325"],"generic_name":["DALBAVANCIN"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["DALBAVANCIN HYDROCHLORIDE"],"manufacturer_name":["Teva Pharmaceuticals, Inc."],"application_number":["ANDA219465"],"is_original_packager":[true]},"version":"3","pregnancy":["8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies with dalbavancin for injection use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse developmental outcomes. No treatment-related malformations or embryo-fetal toxicity were observed in pregnant rats or rabbits at clinically relevant exposures of dalbavancin. Treatment of pregnant rats with dalbavancin at 3.5 times the human dose on an exposure basis during early embryonic development and from implantation to the end of lactation resulted in delayed fetal maturation and increased fetal loss, respectively [ see Data ] . The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data No evidence of embryo or fetal toxicity was found in the rat or rabbit at a dose of 15 mg/kg/day (1.2 and 0.7 times the human dose on an exposure basis, respectively). Delayed fetal maturation was observed in the rat at a dose of 45 mg/kg/day (3.5 times the human dose on an exposure basis). In a rat prenatal and postnatal development study, increased embryo lethality and increased offspring deaths during the first week post-partum were observed at a dose of 45 mg/kg/day (3.5 times the human dose on an exposure basis)."],"overdosage":["10 OVERDOSAGE Specific information is not available on the treatment of overdose with dalbavancin for injection, as dose-limiting toxicity has not been observed in clinical studies. In Phase 1 studies, healthy volunteers have been administered cumulative doses of up to 4,500 mg over a period of up to 8 weeks (not an approved dosing regimen), with no signs of toxicity or laboratory results of clinical concern. Treatment of overdose with dalbavancin for injection should consist of observation and general supportive measures. Although no information is available specifically regarding the use of hemodialysis to treat overdose, in a Phase 1 study in patients with renal impairment less than 6% of the recommended dalbavancin dose was removed [see Clinical Pharmacology ( 12.3 )]."],"description":["11 DESCRIPTION Dalbavancin for injection is a lipoglycopeptide antibacterial synthesized from a fermentation product of Nonomuraea species. Dalbavancin is a mixture of five closely related active homologs (A 0 , A 1 , B 0 , B 1 , and B 2 ); the component B 0 is the major component of dalbavancin. The homologs share the same core structure and differ in the fatty acid side chain of the N-acylaminoglucuronic acid moiety (R 1 ) structure and/or the presence of an additional methyl group (R 2 ) on the terminal amino group (shown in the Figure 1 and Table 3 below). Figure 1. Dalbavancin Structural Formula Table 3. Substitution Patterns for Dalbavancin API Homologs Dalbavancin R 1 R 2 Molecular Formula Molecular Weight * A 0 CH(CH 3 ) 2 H C 87 H 98 N 10 O 28 Cl 2 · 1.6 HCl 1,802.7 A 1 CH 2 CH 2 CH 3 H C 87 H 98 N 10 O 28 Cl 2 · 1.6 HCl 1,802.7 B 0 CH 2 CH(CH 3 ) 2 H C 88 H 100 N 10 O 28 Cl 2 · 1.6 HCl 1,816.7 B 1 CH 2 CH 2 CH 2 CH 3 H C 88 H 100 N 10 O 28 Cl 2 · 1.6 HCl 1,816.7 B 2 CH 2 CH(CH 3 ) 2 CH 3 C 89 H 102 N 10 O 28 Cl 2 · 1.6 HCl 1,830.7 *Anhydrous free base The B 0 INN chemical name is: 5,31-dichloro-38-de(methoxycarbonyl)-7-demethyl-19-deoxy-56-O-[2-deoxy-2-[(10-methylundecanoyl)amino]-β-D-glucopyranuronosyl]-38-[[3-(dimethylamino)propyl] carbamoyl]-42-O-α-D-mannopyranosyl-15-N-methyl(ristomycin A aglycone) hydrochloride. Dalbavancin for injection is supplied in clear glass vials as a sterile, lyophilized, preservative-free, white to off-white to pale yellow solid. Each vial contains dalbavancin hydrochloride equivalent to 500 mg of dalbavancin as the free base, plus lactose monohydrate (129 mg) and mannitol (129 mg) as excipients. Sodium hydroxide or hydrochloric acid may be added to adjust the pH at the time of manufacture. The powder is to be reconstituted and further diluted for intravenous infusion [ see Dosage and Administration ( 2.4 ) , How Supplied/Storage and Handling ( 16 ) ] . Figure 1. Dalbavancin Structural Formula"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Dalbavancin for injection is supplied as a white/off-white to pale yellow sterile lyophilized powder in a single-dose glass vial containing dalbavancin hydrochloride equivalent to 500 mg dalbavancin: Package of 1 individual vial (500 mg/vial) in carton: (NDC 0480-3325-01) Dalbavancin for injection should be stored at 25ºC (77ºF); excursions permitted to 15ºC to 30ºC (59ºF to 86ºF) [see USP Controlled Room Temperature]. Storage of the reconstituted and diluted solutions of dalbavancin for injection are described elsewhere in the prescribing information [see Dosage and Administration ( 2.4 )]."],"microbiology":["12.4 Microbiology Mechanism of Action Dalbavancin, a semisynthetic lipoglycopeptide, interferes with cell wall synthesis by binding to the D-alanyl-D-alanine terminus of the stem pentapeptide in nascent cell wall peptidoglycan, thus preventing cross-linking. Dalbavancin is bactericidal in vitro against Staphylococcus aureus and Streptococcus pyogenes at concentrations similar to those sustained throughout treatment in humans treated according to the recommended dosage regimen. Resistance The development of bacterial isolates resistant to dalbavancin has not been observed, either in vitro , in studies using serial passage, or in animal infection experiments. Interaction with Other Antimicrobials When tested in vitro , dalbavancin demonstrated synergistic interactions with oxacillin and did not demonstrate antagonistic or synergistic interactions with any of the following antibacterial agents of various classes: gentamicin, vancomycin, levofloxacin, clindamycin, quinupristin/dalfopristin, linezolid, aztreonam, rifampin or daptomycin. The clinical significance of these in vitro findings is unknown. Antimicrobial Activity Dalbavancin has been shown to be active against the following microorganisms, both in vitro and in clinical infections [s ee Indications and Usage ( 1 ) ] . Aerobic bacteria Gram-positive bacteria Staphylococcus aureus (including methicillin-resistant isolates) Streptococcus pyogenes Streptococcus agalactiae Streptococcus dysgalactiae Streptococcus anginosus group (including S. anginosus, S. intermedius, S. constellatus ) Enterococcus faecali s (vancomycin-susceptible isolates only) The following in vitro data are available, but their clinical significance is unknown. At least 90 percent of the following bacteria exhibit an in vitro minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for dalbavancin against isolates of similar genus or organism group. However, the efficacy of dalbavancin in treating clinical infections caused by these bacteria has not been established in adequate well-controlled clinical trials. Aerobic bacteria Gram-positive bacteria Enterococcus faecium (vancomycin-susceptible isolates only) Susceptibility Testing For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC."],"geriatric_use":["8. 5 Geriatric Use Of the 2,473 patients treated with dalbavancin for injection in Phase 2 and 3 clinical trials, 403 patients (16.3%) were 65 years of age or older. The efficacy and tolerability of dalbavancin for injection were similar to comparator regardless of age. The pharmacokinetics of dalbavancin for injection was not significantly altered with age; therefore, no dosage adjustment is necessary based on age alone. Dalbavancin for injection is substantially excreted by the kidney, and the risk of adverse reactions may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection in this age group."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of dalbavancin for injection for the treatment of ABSSSI has been established in pediatric patients aged birth to less than 18 years. Use of dalbavancin for injection for this indication is supported by evidence from adequate and well-controlled studies in adults with additional pharmacokinetic and safety data in pediatric patients aged birth to less than 18 years [see Adverse Reactions ( 6.1 ), Clinical Pharmacology ( 12.3 ), and Clinical Studies (14.1)] . There is insufficient information to recommend dosage adjustment for pediatric patients with ABSSSI and CLcr less than 30 mL/min/1.73m 2 [see Dosage and Administration ( 2.2 )]."],"effective_time":"20251006","clinical_studies":["14 CLINICAL STUDIES Clinical Studies of Dalbavancin for Injection in Adult Patients with Acute Bacterial Skin and Skin Structure Infections Dalbavancin for Injection 1,500 mg Single Dose Regimen Adult patients with ABSSSI were enrolled in a Phase 3, double-blind, clinical trial. The ITT population included 698 patients who were randomized to dalbavancin for injection treatment with either a single 1,500 mg dose or another dalbavancin dosing regimen (Trial 3). Patients with creatinine clearance less than 30 mL/min had their dose adjusted (Section 2.2). Approximately 5% of patients also received a protocol-specified empiric course of treatment with intravenous aztreonam for coverage of Gram-negative pathogens. The specific infections and other patient characteristics in this trial were similar to those described above for previous ABSSSI trials. The primary endpoint in this ABSSSI trial was the clinical response rate where responders were defined as patients who had at least a 20% decrease from baseline in lesion area 48 to 72 hours after randomization without receiving any rescue antibacterial therapy. The secondary endpoint was the clinical success rate at a follow-up visit occurring between Days 26 and 30, with clinical success defined as having at least a 90% decrease from baseline in lesion size, a temperature of 37.6°C or lower, and meeting pre-specified criteria for local signs: purulent discharge and drainage absent or mild and improved from baseline (for patients with wound infections), heat/warmth and fluctuance absent, swelling/induration and tenderness to palpation absent or mild. Table 9 summarizes results for these two endpoints in the ITT population. Note that there are insufficient historical data to establish the magnitude of drug effect for antibacterial drugs compared with placebo at the follow-up visit. Therefore, comparisons between treatment groups based on clinical success rates at this visit cannot be utilized to establish non-inferiority. Table 9. Primary and Another Dalbavancin Dosing Regimen Efficacy Results in ABSSSI Patients (Trial 3) 1,2 Dalbavancin for Injection, n/N (%) Single Dose (1,500 mg) Another Dalbavancin Dosing Regimen Difference (95% CI) 3 Clinical Responders at 48 to 72 Hours (ITT) 284/349 (81.4) 294/349 (84.2) -2.9 (-8.5, 2.8) Clinical Success at Day 26 to 30 (ITT) 295/349 (84.5) 297/349 (85.1) -0.6 (-6.0, 4.8) Clinical Success at Day 26 to 30 (CE) 250/271 (92.3) 247/267 (92.5) -0.3 (-4.9, 4.4) 1 There were 3 patients in another dalbavancin dosing regimen group who did not receive treatment and were counted as non-responders. 2 Patients who died or used non-study antibacterial therapy or had missing measurements were classified as non-responders. 3 The 95% Confidence Interval (CI) is computed using the Miettinen and Nurminen approach. Abbreviations: ITT-intent to treat; CE-clinically evaluable Table 10 shows outcomes in patients with an identified baseline pathogen from Trial 3 in the microbiological ITT (microITT) population. The outcomes shown in the table are clinical response rates at 48 to 72 hours and clinical success rates at follow-up (Day 26 to 30), as defined above. Table 10. Outcomes by Baseline Pathogen (Trial 3; MicroITT) Early Clinical Response at 48 to 72 hours ≥ 20% reduction in lesion size Clinical Success at Day 26 to 30 Pathogen Single dose (1,500 mg) n/N (%) Another Dalbavancin Dosing Regimen Single dose (1,500 mg) n/N (%) Another Dalbavancin Dosing Regimen Staphylococcus aureus 123/139 (88.5) 133/156 (85.3) 124/139 (89.2) 140/156 (89.7) Methicillin-susceptible Methicillin-resistant 92/103 (89.3) 31/36 (86.1) 89/96 (89.6) 48/61 (78.7) 93/103 (90.3) 31/36 (86.1) 86/96 (89.6) 55/61 (90.2) Streptococcus agalactiae 6/6(100.0) 4/6 (66.7) 5/6 (83.3) 5/6 (83.3) Streptococcus anginosus group 31/33 (93.9) 19/19 (100.0) 29/33 (87.9) 17/19 (89.5) Streptococcus pyogenes 14/14 (100.0) 18/22 (81.8) 13/14 (92.9) 19/22 (86.4) Enterococcus faecalis 4/4 (100.0) 8/10 (80.0) 4/4 (100.0) 9/10 (90.0) In Trials 1, 2, and 3, all patients had blood cultures obtained at baseline. A total of 40 ABSSSI patients who received dalbavancin for injection had bacteremia at baseline caused by one or more of the following bacteria: 26 S. aureus (21 MSSA and 5 MRSA), 6 S. agalactiae , 7 S. pyogenes , 2 S. anginosus group, and 1 E. faecalis . In patients who received dalbavancin for injection, a total of 34/40 (85%) were clinical responders at 48 to 72 hours and 32/40 (80%) were clinical successes at Day 26 to 30. Clinical Study of Dalbavancin for Injection in Pediatric Patients with Acute Bacterial Skin and Skin Structure Infections The pediatric trial was a multicenter, open-label, randomized, actively controlled trial (NCT02814916, Trial 4) conducted in pediatric patients 3 months of age to less than 18 years with ABSSSI, not known or expected to be caused exclusively by Gram-negative organisms. Patients were randomized in a 3:3:1 ratio to receive either dalbavancin for injection single-dose regimen, another dalbavancin dosing regimen, or comparator. The comparator regimens included intravenous vancomycin for methicillin-resistant Gram-positive infections, or intravenous oxacillin or flucloxacillin for methicillin-susceptible Gram-positive infections. Patients in the comparator arm received intravenous treatment for a minimum of 72 hours before an optional switch to oral therapy to complete a total of 10 to 14 days of antibacterial drug therapy. Additional 5 patients from birth to < 3 months of age were enrolled and assigned to the dalbavancin for injection single-dose regimen. A study population of 191 pediatric patients received study medication (dalbavancin for injection single dose regimen n=83, another dalbavancin dosing regimen n=78, comparator n=30); 62% of the patients were male and 89% were white, and 83% were from Eastern Europe. The pediatric age groups who received dalbavancin for injection were as follows: 12 to < 18 years (n=58), 6 to < 12 years (n=49), 2 to < 6 years (n=35), 3 months to < 2 years (n=14), and birth < 3 months (n=5). Patients had diagnoses of major cutaneous abscess (53%), cellulitis (29%), or surgical site/traumatic wound infection (18%). The predominant pathogen at baseline was Staphylococcus aureus (84%). The primary objective was to evaluate the safety and tolerability of dalbavancin for injection. The trial was not powered for a comparative inferential efficacy analysis. Efficacy was assessed in the modified intent-to­treat population (n=183) which included all randomized patients who received any dose of study drug and had a diagnosis of ABSSSI caused by Gram-positive organism(s). Patients with ABSSSI only caused by Gram-negative organisms were excluded. The five patients in the age group birth to < 3 months of age were not included in efficacy analyses since they were enrolled with expanded inclusion criteria and only received the single dose dalbavancin for injection regimen. An early clinical response at 48 to 72 hours was defined as ≥ 20% reduction in lesion size compared to baseline and no receipt of rescue antibacterial therapy. The proportion of patients with early clinical response, was 97.3% (73/75) in the dalbavancin for injection single-dose arm, 93.6% (73/78) in another dalbavancin dosing regimen arm, and 86.7% (26/30) in the comparator arm. The difference in responder rates between the dalbavancin single-dose and comparator arms was 10.7%, with an exact 97.5% confidence interval (CI) of (-1.7%, 31.6%). The difference in responder rates between another dalbavancin dosing regimen and comparator arms was 6.9%, with an exact 97.5% CI of (-6.4%, 27.7%). Clinical cure was defined as resolution of the clinical signs and symptoms of infection, when compared to baseline, and no additional antibacterial treatment for the disease under study. In patients, 3 months of age or older in the mITT population, the clinical cure rate at the test of cure (TOC) visit (28 ± 2 days) was 94.7% (71/75) in the dalbavancin for injection single-dose arm, 92.3% (72/78) in another dalbavancin dosing regimen arm and 100% (30/30) in the comparator arm. The difference in cure rates between the dalbavancin single-dose and comparator arms was -5.3%, with an exact 97.5% CI of (-15.1%, 10.5%). The difference in cure rates between another dalbavancin dosing regimen and comparator arms was -7.7%, with an exact 97.5% CI of (-17.9%, 8.3%)."],"pharmacodynamics":["12.2 Pharmacodynamics The antibacterial activity of dalbavancin appears to best correlate with the ratio of area under the concentration-time curve to minimal inhibitory concentration (AUC/MIC) for Staphylococcus aureus based on animal models of infection. Cardiac Electrophysiology In a randomized, positive- and placebo-controlled, thorough QT/QTc study, 200 healthy subjects received dalbavancin 1,000 mg intravenous, dalbavancin 1,500 mg intravenous, oral moxifloxacin 400 mg, or placebo. Neither dalbavancin 1,000 mg nor dalbavancin 1,500 mg had any clinically relevant adverse effect on cardiac repolarization."],"pharmacokinetics":["12.3 Pharmacokinetics General Pharmacokinetic Properties Dalbavancin pharmacokinetic parameters have been characterized in healthy subjects, patients, and specific populations. Pharmacokinetic parameters following administration of single intravenous 1,000 mg and 1,500 mg doses were as shown in Table 4. The pharmacokinetics of dalbavancin can be described using a three-compartment model. Table 4. Dalbavancin Pharmacokinetic Parameters in Healthy Subjects Parameter Single 1,000 mg Dose Single 1,500 mg Dose C max (mg/L) 287 (13.9) 1 423 (13.2) 4 AUC 0-24 (mg•h/L) 3,185 (12.8) 1 4,837 (13.7) 4 AUC 0-Day7 (mg•h/L) 11,160 (41.1) 2 ND AUC 0- inf (mg•h/L) 23,443 (40.9) 2 ND Terminal t 1/2 (h) 346 (16.5) 2,3 ND CL (L/h) 0.0513 (46.8) 2 ND All values are presented as mean (% coefficient of variation) 1 Data from 50 healthy subjects. 2 Data from 12 healthy subjects. 3 Based upon population pharmacokinetic analyses of data from patients, the effective half-life is approximately 8.5 days (204 hours). 4 Data from 49 healthy subjects. Abbreviation: ND – not determined In healthy subjects, dalbavancin AUC 0-24h and C max both increased proportionally to dose following single intravenous dalbavancin doses ranging from 140 mg to 1,500 mg, indicating linear pharmacokinetics. No apparent accumulation of dalbavancin was observed following multiple intravenous infusions administered once weekly for up to eight weeks, with 1,000 mg on Day 1 followed by up to seven weekly 500 mg doses, in healthy adults with normal renal function. Distribution Dalbavancin is reversibly bound to human plasma proteins, primarily to albumin. The plasma protein binding of dalbavancin is approximately 93% and is not altered as a function of drug concentration, renal impairment, or hepatic impairment. The mean concentrations of dalbavancin achieved in skin blister fluid remain above 30 mg/L up to 7 days (approximately 146 hours) post dose, following 1,000 mg intravenous dalbavancin. The mean ratio of the AUC 0-144 hrs in skin blister fluid/AUC 0-144 hrs in plasma is 0.60 (range 0.44 to 0.64). Metabolism In vitro studies using human microsomal enzymes and hepatocytes indicate that dalbavancin is not a substrate, inhibitor, or inducer of CYP450 isoenzymes. A minor metabolite of dalbavancin (hydroxy-dalbavancin) has been observed in the urine of healthy subjects. Quantifiable concentrations of the hydroxy-dalbavancin metabolite have not been observed in human plasma (lower limit of quantitation = 0.4 mcg/mL) [see Drug Interactions ( 7.2 )] . Excretion Following administration of a single 1,000 mg dose in healthy subjects, 20% of the dose was excreted in feces through 70 days post dose. An average of 33% of the administered dalbavancin dose was excreted in urine as unchanged dalbavancin and approximately 12% of the administered dose was excreted in urine as the metabolite hydroxy-dalbavancin through 42 days post dose. Specific Populations Renal Impairment The pharmacokinetics of dalbavancin were evaluated in 28 subjects with varying degrees of renal impairment and in 15 matched control subjects with normal renal function. Following a single dose of 500 mg or 1,000 mg dalbavancin, the mean plasma clearance (CL T ) was reduced 11%, 35%, and 47% in subjects with CLcr 50 to 79 mL/min, CLcr 30 to 49 mL/min, and CLcr less than 30 mL/min, respectively, compared to subjects with normal renal function. The clinical significance of the decrease in mean plasma CL T , and the associated increase in AUC 0-∞ noted in these pharmacokinetic studies of dalbavancin in subjects with CLcr less than 30 mL/min has not been established [ see Dosage and Administration ( 2.3 ) , Use in Specific Populations ( 8.6 )] . Dalbavancin pharmacokinetic parameters in subjects with end-stage renal disease receiving regularly scheduled hemodialysis (three times/week) are similar to those observed in subjects with mild to moderate renal impairment, and less than 6% of an administered dose is removed after three hours of hemodialysis. Therefore, no dosage adjustment is recommended for patients receiving regularly scheduled hemodialysis, and dalbavancin may be administered without regard to the timing of hemodialysis in such patients [see Dosage and Administration ( 2.1 ) , Overdosage ( 10 ) ]. Hepatic Impairment The pharmacokinetics of dalbavancin were evaluated in 17 subjects with mild, moderate, or severe hepatic impairment (Child-Pugh class A, B or C) and compared to those in nine matched healthy subjects with normal hepatic function. The mean AUC 0-336 hrs was unchanged in subjects with mild hepatic impairment compared to subjects with normal hepatic function; however, the mean AUC 0-336 hrs decreased 28% and 31% in subjects with moderate and severe hepatic impairment respectively, compared to subjects with normal hepatic function. The clinical significance of the decreased AUC 0-336 hrs in subjects with moderate and severe hepatic function is unknown. No dosage adjustment is recommended for patients with mild hepatic impairment. Caution should be exercised when prescribing dalbavancin to patients with moderate or severe hepatic impairment as no data are available to determine the appropriate dosing. Gender Clinically significant gender-related differences in dalbavancin pharmacokinetics have not been observed either in healthy subjects or in patients with infections. No dosage adjustment is recommended based on gender. Geriatric Patients Clinically significant age-related differences in dalbavancin pharmacokinetics have not been observed in patients with infections. No dosage adjustment is recommended based solely on age. Pediatric Patients The pharmacokinetics of dalbavancin has been evaluated in 211 individual pediatric patients [4 days to 17.9 years of age, including a preterm neonate (gestational age 36 weeks; n=1) and term neonates (gestational age 37 to 40 weeks; n=4)] with CLcr 30 mL/min/1.73 m 2 and above. There is insufficient information to assess the exposure of dalbavancin for injection in the pediatric patients with CLcr less than 30 mL/min/1.73 m 2 . No clinically important differences in drug exposure between pediatric age groups (including preterm neonates) and adults are expected following administration of the age-dependent recommended single dose of dalbavancin for injection. The median plasma AUC from 0 to 120 hours (AUC 0-120h ) of dalbavancin in pediatric patient age groups from term neonates at birth to less than 18 years is expected to be comparable to that in adult patients (AUC 0-120h , 10,400 mg*h/L). The expected median plasma AUC 0-120h of dalbavancin in preterm neonates at birth (gestational age 26 weeks to <37 weeks) was approximately 62% of that in adult patients. The expected median maximum plasma concentrations (C max ) of dalbavancin for pediatric patient age groups ranged between approximately 53% to 73% of that in adult patients (C max , 412 mg/L). However, in all pediatric age groups, the percentage of patients attaining PK/PD targets related to in vivo drug activity were above 90% or higher for MICs up to 0.25 mg/L. Drug Interactions Nonclinical studies demonstrated that dalbavancin is not a substrate, inhibitor, or inducer of CYP450 isoenzymes. In a population pharmacokinetic analysis, dalbavancin pharmacokinetics were not affected by co-administration with known CYP450 substrates, inducers or inhibitors, nor by individual medications including acetaminophen, aztreonam, fentanyl, metronidazole, furosemide, proton pump inhibitors (omeprazole, esomeprazole, pantoprazole, lansoprazole), midazolam, and simvastatin."],"adverse_reactions":["6 ADVERSE REACTIONS The following clinically significant adverse reactions are also discussed elsewhere in the labeling: Hypersensitivity Reactions [see Warnings and Precautions ( 5.1 )] Infusion Related Reactions [see Warnings and Precautions ( 5.2 )] Hepatic Effects [see Warnings and Precautions ( 5.3 )] Clostridioides difficile -associated Diarrhea [see Warnings and Precautions ( 5.4 )] The most common adverse reactions occurring in >4% of adult patients treated with dalbavancin for injection were nausea, headache, and diarrhea. The most common adverse reaction that occurred in >1% of pediatric patients was pyrexia. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Teva at 1­888-838-2872 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of dalbavancin for injection cannot be directly compared to rates in the clinical trials of another drug and may not reflect rates observed in practice. Clinical Trials Experience in Adult Patients Adverse reactions were evaluated for 2,473 patients treated with dalbavancin for injection: 1,778 patients were treated with dalbavancin for injection in seven Phase 2/3 trials comparing dalbavancin for injection to comparator antibacterial drugs and 695 patients were treated with dalbavancin for injection in one Phase 3 trial comparing dalbavancin for injection single-dose and another dalbavancin dosing regimen. The median age of patients treated with dalbavancin for injection was 48 years, ranging between 16 and 93 years. Patients treated with dalbavancin for injection were predominantly male (59.5%) and White (81.2%). Serious Adverse Reactions and Adverse Reactions Leading to Discontinuation Serious adverse reactions occurred in 121/2,473 (4.9%) of patients treated with any regimen of dalbavancin for injection. In the Phase 2/3 trials comparing dalbavancin for injection to comparator, serious adverse reactions occurred in 109/1,778 (6.1%) of patients in the dalbavancin for injection group and 80/1,224 (6.5%) of patients in the comparator group. In a Phase 3 trial comparing dalbavancin for injection single-dose and another dalbavancin dosing regimen, serious adverse reactions occurred in 7/349 (2.0%) of patients in the dalbavancin for injection single dose group and 5/346 (1.4%) of patients in another dalbavancin dosing regimen group. Dalbavancin for injection was discontinued due to an adverse reaction in 64/2,473 (2.6%) patients treated with any regimen of dalbavancin for injection. In the Phase 2/3 trials comparing dalbavancin for injection to comparator, dalbavancin for injection was discontinued due to an adverse reaction in 53/1,778 (3.0%) of patients in the dalbavancin for injection group and 35/1,224 (2.9%) of patients in the comparator group. In a Phase 3 trial comparing dalbavancin for injection single-dose and another dalbavancin dosing regimen, dalbavancin for injection was discontinued due to an adverse reaction in 6/349 (1.7%) of patients in the dalbavancin for injection single dose group and 5/346 (1.4%) of patients in another dalbavancin dosing regimen group. Most Common Adverse Reactions The most common adverse reactions in patients treated with dalbavancin for injection in Phase 2/3 trials were nausea (5.5%), headache (4.7%), and diarrhea (4.4%). The median duration of adverse reactions was 3.0 days in patients treated with dalbavancin for injection. In the Phase 2/3 trials comparing dalbavancin for injection to comparator, the median duration of adverse reactions was 3.0 days for patients in the dalbavancin for injection group and 4.0 days in patients in the comparator group. In a Phase 3 trial comparing dalbavancin for injection single-dose and another dalbavancin dosing regimen, the median duration of adverse reactions was 3.0 days for patients in the dalbavancin for injection single-dose and another dalbavancin dosing regimen group. Table 2 lists selected adverse reactions occurring in 2% or more of patients treated with dalbavancin for injection in Phase 2/3 clinical trials. Table 2. Selected Adverse Reactions Occurring in ≥ 2% of Patients Receiving Dalbavancin for Injection in Phase 2/3 Trials (Number (%) of Patients) Adverse Reactions Dalbavancin for Injection Comparator* (N = 1,778) (N = 1,224) Nausea 98 (5.5) 78 (6.4) Diarrhea 79 (4.4) 72 (5.9) Headache 83 (4.7) 59 (4.8) Vomiting 50 (2.8) 37 (3) Rash 48 (2.7) 30 (2.4) Pruritus 38 (2.1) 41 (3.3) * Comparators included linezolid, cefazolin, cephalexin, and vancomycin. In the Phase 3 trial comparing the single dose and another dalbavancin for injection dosing regimen the adverse reaction that occurred in 2% or more of patients treated with dalbavancin for injection was nausea (3.4% in the dalbavancin for injection single dose group and 2% in another dalbavancin dosing regimen group). The following selected adverse reactions were reported in dalbavancin for injection treated patients at a rate of less than 2% in these clinical trials: Blood and lymphatic system disorders : anemia, hemorrhagic anemia, leucopenia, neutropenia, thrombocytopenia, petechiae, eosinophilia, thrombocytosis Gastrointestinal d isorders : gastrointestinal hemorrhage, melena, hematochezia, abdominal pain General d isorders and administration site conditions : infusion-related reactions Hepatobiliary disorders : hepatotoxicity Immune system disorders : anaphylactic reaction Infections and infestations : Clostridioides difficile colitis, oral candidiasis, vulvovaginal mycotic infection Investigations : hepatic transaminases increased, blood alkaline phosphatase increased, international normalized ratio increased, blood lactate dehydrogenase increased, gamma-glutamyl transferase increased Metaboli sm and nutrition disorders : hypoglycemia Nervous s ystem disorders : dizziness Respiratory, thoracic and media s tinal disorders : bronchospasm Skin and s ubcutaneous t issue d isorders : rash, pruritus, urticaria Vascular disorders : flushing, phlebitis, wound hemorrhage, spontaneous hematoma Alanine Aminotransferase (ALT) Elevations Among patients with normal baseline ALT levels treated with dalbavancin for injection 17 (0.8%) had post-baseline ALT elevations greater than 3 times the upper limit of normal (ULN) including five subjects with post-baseline ALT values greater than 10 times ULN. Among patients with normal baseline ALT levels treated with non-dalbavancin for injection comparators 2 (0.2%) had post-baseline ALT elevations greater than 3 times the upper limit of normal. Fifteen of the 17 patients treated with dalbavancin for injection and one comparator patient had underlying conditions which could affect liver enzymes, including chronic viral hepatitis, history of alcohol abuse and metabolic syndrome. In addition, one dalbavancin for injection-treated subject in a Phase 1 trial had post-baseline ALT elevations greater than 20 times ULN. ALT elevations were reversible in all subjects with follow-up assessments. No comparator-treated subject with normal baseline transaminases had post-baseline ALT elevation greater than 10 times ULN. Clinical Trials Experience in Pediatric Patients Adverse reactions were evaluated in one Phase 3 pediatric clinical trial which included 161 pediatric patients from birth to less than 18 years of age with ABSSSI treated with dalbavancin for injection (83 patients treated with a single dose of dalbavancin for injection and 78 patients treated with another dalbavancin dosing regimen) and 30 patients treated with comparator agents for a treatment period up to 14 days. The median age of pediatric patients treated with dalbavancin for injection was 9 years, ranging from birth to <18 years. The majority of patients were male (62.3%) and White (89.0%). The safety findings of dalbavancin for injection in pediatric patients were similar to those observed in adults. Serious Adverse Reactions and Adverse Reactions Leading to Discontinuation Serious adverse reactions (SARs) occurred in 3/161 (1.9%) of patients treated with dalbavancin for injection, all in the single-dose arm. There were no adverse reactions leading to dalbavancin for injection discontinuation. Most Common Adverse Reactions Most common adverse reaction occurring in more than 1% of pediatric patients 2/161 (1.2%) was pyrexia. Other Adverse Reactions The following selected adverse reactions were reported in dalbavancin for injection-treated patients at a rate of less than 1% in this pediatric clinical trial: Gastrointestinal disorders : diarrhea Nervous system disorders : dizziness Skin and subcutaneous tissue disorders : pruritus 6.2 Post Marketing Experience The following adverse reaction has been identified during post-approval use of dalbavancin. Because the reaction is reported voluntarily from a population of uncertain size, it is not possible to reliably estimate the frequency or establish a causal relationship to drug exposure. General disorders and administration site conditions: Back pain as an infusion-related reaction [See Warnings and Precautions ( 5.2 )]."],"contraindications":["4 CONTRAINDICATIONS Dalbavancin for injection is contraindicated in patients with known hypersensitivity to dalbavancin. Known hypersensitivity to dalbavancin ( 4 )"],"description_table":["
Table 3. Substitution Patterns for Dalbavancin API Homologs
DalbavancinR1R2Molecular FormulaMolecular Weight*
A0CH(CH3)2HC87H98N10O28Cl2 · 1.6 HCl1,802.7
A1CH2CH2CH3HC87H98N10O28Cl2 · 1.6 HCl1,802.7
B0CH2CH(CH3)2HC88H100N10O28Cl2 · 1.6 HCl1,816.7
B1CH2CH2CH2CH3HC88H100N10O28Cl2 · 1.6 HCl1,816.7
B2CH2CH(CH3)2CH3C89H102N10O28Cl2 · 1.6 HCl1,830.7
*Anhydrous free base
"],"drug_interactions":["7 DRUG INTERACTIONS 7.1 Drug-Laboratory Test Interactions Drug-laboratory test interactions have not been reported. Dalbavancin for injection at therapeutic concentrations does not artificially prolong prothrombin time (PT) or activated partial thromboplastin time (aPTT). 7.2 Drug-Drug Interactions No clinical drug-drug interaction studies have been conducted with dalbavancin for injection. There is minimal potential for drug-drug interactions between dalbavancin for injection and cytochrome P450 (CYP450) substrates, inhibitors, or inducers [see C linical P harmacology ( 12.3 )] ."],"mechanism_of_action":["12.1 Mechanism of Action Dalbavancin is an antibacterial drug [see Microbiology ( 12.4 )] ."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Dalbavancin is an antibacterial drug [see Microbiology ( 12.4 )] . 12.2 Pharmacodynamics The antibacterial activity of dalbavancin appears to best correlate with the ratio of area under the concentration-time curve to minimal inhibitory concentration (AUC/MIC) for Staphylococcus aureus based on animal models of infection. Cardiac Electrophysiology In a randomized, positive- and placebo-controlled, thorough QT/QTc study, 200 healthy subjects received dalbavancin 1,000 mg intravenous, dalbavancin 1,500 mg intravenous, oral moxifloxacin 400 mg, or placebo. Neither dalbavancin 1,000 mg nor dalbavancin 1,500 mg had any clinically relevant adverse effect on cardiac repolarization. 12.3 Pharmacokinetics General Pharmacokinetic Properties Dalbavancin pharmacokinetic parameters have been characterized in healthy subjects, patients, and specific populations. Pharmacokinetic parameters following administration of single intravenous 1,000 mg and 1,500 mg doses were as shown in Table 4. The pharmacokinetics of dalbavancin can be described using a three-compartment model. Table 4. Dalbavancin Pharmacokinetic Parameters in Healthy Subjects Parameter Single 1,000 mg Dose Single 1,500 mg Dose C max (mg/L) 287 (13.9) 1 423 (13.2) 4 AUC 0-24 (mg•h/L) 3,185 (12.8) 1 4,837 (13.7) 4 AUC 0-Day7 (mg•h/L) 11,160 (41.1) 2 ND AUC 0- inf (mg•h/L) 23,443 (40.9) 2 ND Terminal t 1/2 (h) 346 (16.5) 2,3 ND CL (L/h) 0.0513 (46.8) 2 ND All values are presented as mean (% coefficient of variation) 1 Data from 50 healthy subjects. 2 Data from 12 healthy subjects. 3 Based upon population pharmacokinetic analyses of data from patients, the effective half-life is approximately 8.5 days (204 hours). 4 Data from 49 healthy subjects. Abbreviation: ND – not determined In healthy subjects, dalbavancin AUC 0-24h and C max both increased proportionally to dose following single intravenous dalbavancin doses ranging from 140 mg to 1,500 mg, indicating linear pharmacokinetics. No apparent accumulation of dalbavancin was observed following multiple intravenous infusions administered once weekly for up to eight weeks, with 1,000 mg on Day 1 followed by up to seven weekly 500 mg doses, in healthy adults with normal renal function. Distribution Dalbavancin is reversibly bound to human plasma proteins, primarily to albumin. The plasma protein binding of dalbavancin is approximately 93% and is not altered as a function of drug concentration, renal impairment, or hepatic impairment. The mean concentrations of dalbavancin achieved in skin blister fluid remain above 30 mg/L up to 7 days (approximately 146 hours) post dose, following 1,000 mg intravenous dalbavancin. The mean ratio of the AUC 0-144 hrs in skin blister fluid/AUC 0-144 hrs in plasma is 0.60 (range 0.44 to 0.64). Metabolism In vitro studies using human microsomal enzymes and hepatocytes indicate that dalbavancin is not a substrate, inhibitor, or inducer of CYP450 isoenzymes. A minor metabolite of dalbavancin (hydroxy-dalbavancin) has been observed in the urine of healthy subjects. Quantifiable concentrations of the hydroxy-dalbavancin metabolite have not been observed in human plasma (lower limit of quantitation = 0.4 mcg/mL) [see Drug Interactions ( 7.2 )] . Excretion Following administration of a single 1,000 mg dose in healthy subjects, 20% of the dose was excreted in feces through 70 days post dose. An average of 33% of the administered dalbavancin dose was excreted in urine as unchanged dalbavancin and approximately 12% of the administered dose was excreted in urine as the metabolite hydroxy-dalbavancin through 42 days post dose. Specific Populations Renal Impairment The pharmacokinetics of dalbavancin were evaluated in 28 subjects with varying degrees of renal impairment and in 15 matched control subjects with normal renal function. Following a single dose of 500 mg or 1,000 mg dalbavancin, the mean plasma clearance (CL T ) was reduced 11%, 35%, and 47% in subjects with CLcr 50 to 79 mL/min, CLcr 30 to 49 mL/min, and CLcr less than 30 mL/min, respectively, compared to subjects with normal renal function. The clinical significance of the decrease in mean plasma CL T , and the associated increase in AUC 0-∞ noted in these pharmacokinetic studies of dalbavancin in subjects with CLcr less than 30 mL/min has not been established [ see Dosage and Administration ( 2.3 ) , Use in Specific Populations ( 8.6 )] . Dalbavancin pharmacokinetic parameters in subjects with end-stage renal disease receiving regularly scheduled hemodialysis (three times/week) are similar to those observed in subjects with mild to moderate renal impairment, and less than 6% of an administered dose is removed after three hours of hemodialysis. Therefore, no dosage adjustment is recommended for patients receiving regularly scheduled hemodialysis, and dalbavancin may be administered without regard to the timing of hemodialysis in such patients [see Dosage and Administration ( 2.1 ) , Overdosage ( 10 ) ]. Hepatic Impairment The pharmacokinetics of dalbavancin were evaluated in 17 subjects with mild, moderate, or severe hepatic impairment (Child-Pugh class A, B or C) and compared to those in nine matched healthy subjects with normal hepatic function. The mean AUC 0-336 hrs was unchanged in subjects with mild hepatic impairment compared to subjects with normal hepatic function; however, the mean AUC 0-336 hrs decreased 28% and 31% in subjects with moderate and severe hepatic impairment respectively, compared to subjects with normal hepatic function. The clinical significance of the decreased AUC 0-336 hrs in subjects with moderate and severe hepatic function is unknown. No dosage adjustment is recommended for patients with mild hepatic impairment. Caution should be exercised when prescribing dalbavancin to patients with moderate or severe hepatic impairment as no data are available to determine the appropriate dosing. Gender Clinically significant gender-related differences in dalbavancin pharmacokinetics have not been observed either in healthy subjects or in patients with infections. No dosage adjustment is recommended based on gender. Geriatric Patients Clinically significant age-related differences in dalbavancin pharmacokinetics have not been observed in patients with infections. No dosage adjustment is recommended based solely on age. Pediatric Patients The pharmacokinetics of dalbavancin has been evaluated in 211 individual pediatric patients [4 days to 17.9 years of age, including a preterm neonate (gestational age 36 weeks; n=1) and term neonates (gestational age 37 to 40 weeks; n=4)] with CLcr 30 mL/min/1.73 m 2 and above. There is insufficient information to assess the exposure of dalbavancin for injection in the pediatric patients with CLcr less than 30 mL/min/1.73 m 2 . No clinically important differences in drug exposure between pediatric age groups (including preterm neonates) and adults are expected following administration of the age-dependent recommended single dose of dalbavancin for injection. The median plasma AUC from 0 to 120 hours (AUC 0-120h ) of dalbavancin in pediatric patient age groups from term neonates at birth to less than 18 years is expected to be comparable to that in adult patients (AUC 0-120h , 10,400 mg*h/L). The expected median plasma AUC 0-120h of dalbavancin in preterm neonates at birth (gestational age 26 weeks to <37 weeks) was approximately 62% of that in adult patients. The expected median maximum plasma concentrations (C max ) of dalbavancin for pediatric patient age groups ranged between approximately 53% to 73% of that in adult patients (C max , 412 mg/L). However, in all pediatric age groups, the percentage of patients attaining PK/PD targets related to in vivo drug activity were above 90% or higher for MICs up to 0.25 mg/L. Drug Interactions Nonclinical studies demonstrated that dalbavancin is not a substrate, inhibitor, or inducer of CYP450 isoenzymes. In a population pharmacokinetic analysis, dalbavancin pharmacokinetics were not affected by co-administration with known CYP450 substrates, inducers or inhibitors, nor by individual medications including acetaminophen, aztreonam, fentanyl, metronidazole, furosemide, proton pump inhibitors (omeprazole, esomeprazole, pantoprazole, lansoprazole), midazolam, and simvastatin. 12.4 Microbiology Mechanism of Action Dalbavancin, a semisynthetic lipoglycopeptide, interferes with cell wall synthesis by binding to the D-alanyl-D-alanine terminus of the stem pentapeptide in nascent cell wall peptidoglycan, thus preventing cross-linking. Dalbavancin is bactericidal in vitro against Staphylococcus aureus and Streptococcus pyogenes at concentrations similar to those sustained throughout treatment in humans treated according to the recommended dosage regimen. Resistance The development of bacterial isolates resistant to dalbavancin has not been observed, either in vitro , in studies using serial passage, or in animal infection experiments. Interaction with Other Antimicrobials When tested in vitro , dalbavancin demonstrated synergistic interactions with oxacillin and did not demonstrate antagonistic or synergistic interactions with any of the following antibacterial agents of various classes: gentamicin, vancomycin, levofloxacin, clindamycin, quinupristin/dalfopristin, linezolid, aztreonam, rifampin or daptomycin. The clinical significance of these in vitro findings is unknown. Antimicrobial Activity Dalbavancin has been shown to be active against the following microorganisms, both in vitro and in clinical infections [s ee Indications and Usage ( 1 ) ] . Aerobic bacteria Gram-positive bacteria Staphylococcus aureus (including methicillin-resistant isolates) Streptococcus pyogenes Streptococcus agalactiae Streptococcus dysgalactiae Streptococcus anginosus group (including S. anginosus, S. intermedius, S. constellatus ) Enterococcus faecali s (vancomycin-susceptible isolates only) The following in vitro data are available, but their clinical significance is unknown. At least 90 percent of the following bacteria exhibit an in vitro minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for dalbavancin against isolates of similar genus or organism group. However, the efficacy of dalbavancin in treating clinical infections caused by these bacteria has not been established in adequate well-controlled clinical trials. Aerobic bacteria Gram-positive bacteria Enterococcus faecium (vancomycin-susceptible isolates only) Susceptibility Testing For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC."],"indications_and_usage":["1 INDICATION AND USAGE Dalbavancin for injection is a lipoglycopeptide antibacterial indicated for the treatment of adult and pediatric patients with acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible strains of Gram-positive microorganisms. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of dalbavancin for injection and other antibacterial drugs, dalbavancin for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.2 ) 1.1 Acute Bacterial Skin and Skin Structure Infections Dalbavancin for injection is indicated for the treatment of adult and pediatric patients with acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible strains of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant isolates), Streptococcus pyogenes , Streptococcus agalactiae , Streptococcus dysgalactiae , Streptococcus anginosus group (including S. anginosus , S. intermedius , S . constellatus ) and Enterococcus faecalis (vancomycin susceptible isolates). 1.2 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of dalbavancin for injection and other antibacterial agents, dalbavancin for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Serious hypersensitivity (anaphylactic) and skin reactions have been reported in patients treated with dalbavancin for injection. If an allergic reaction occurs, discontinue treatment with dalbavancin for injection and institute appropriate therapy for the allergic reaction. Carefully monitor patients with known hypersensitivity to glycopeptides. ( 5.1 ) Rapid intravenous infusion of dalbavancin for injection can cause flushing of the upper body, urticaria, pruritus, rash, and/or back pain. Stopping or slowing the infusion may result in cessation of these reactions. ( 5.2 ) Alanine Aminotransferase (ALT) elevations with dalbavancin for injection treatment were reported in clinical trials. ( 5.3 , 6.1 ) Clostridioides difficile -associated diarrhea (CDAD) has been reported with nearly all systemic antibacterial agents, including dalbavancin for injection. Evaluate if diarrhea occurs. ( 5.4 ) 5.1 Hypersensitivity Reactions Serious hypersensitivity (anaphylactic) and skin reactions have been reported in patients treated with dalbavancin for injection. If an allergic reaction to dalbavancin for injection occurs, discontinue treatment with dalbavancin for injection and institute appropriate therapy for the allergic reaction. Before using dalbavancin for injection, inquire carefully about previous hypersensitivity reactions to other glycopeptides. Due to the possibility of cross-sensitivity, carefully monitor for signs of hypersensitivity during treatment with dalbavancin for injection in patients with a history of glycopeptide allergy [see Patient Counseling Information ( 17 )] . 5.2 Infusion - Related Reactions Dalbavancin for injection is administered via intravenous infusion, using a total infusion time of 30 minutes to minimize the risk of infusion-related reactions. Rapid intravenous infusions of dalbavancin for injection can cause flushing of the upper body, urticaria, pruritus, rash, and/or back pain. Stopping or slowing the infusion may result in cessation of these reactions. 5.3 Hepatic Effects In Phase 2 and 3 clinical trials, more dalbavancin for injection than comparator-treated subjects with normal baseline transaminase levels had post-baseline alanine aminotransferase (ALT) elevation greater than 3 times the upper limit of normal (ULN). Overall, abnormalities in liver tests (ALT, AST, bilirubin) were reported with similar frequency in the dalbavancin for injection and comparator arms [see Adverse Reactions ( 6.1 )]. 5.4 Clostridioides difficile - Associated Diarrhea Clostridioides difficile -associated diarrhea (CDAD) has been reported in users of nearly all systemic antibacterial drugs, including dalbavancin for injection, with severity ranging from mild diarrhea to fatal colitis. Treatment with antibacterial agents can alter the normal flora of the colon and may permit overgrowth of C. difficile . C . difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin-producing strains of C . difficile cause increased morbidity and mortality, as these infections can be refractory to antibacterial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial use. Careful medical history is necessary because CDAD has been reported to occur more than 2 months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial use not directed against C . difficile should be discontinued, if possible. Appropriate measures such as fluid and electrolyte management, protein supplementation, antibacterial treatment of C . difficile , and surgical evaluation should be instituted as clinically indicated. 5.5 Development of Drug-Resistant Bacteria Prescribing dalbavancin for injection in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria."],"clinical_studies_table":["
Table 9. Primary and Another Dalbavancin Dosing Regimen Efficacy Results in ABSSSI Patients (Trial 3)1,2
Dalbavancin for Injection, n/N (%)
Single Dose (1,500 mg)Another Dalbavancin Dosing RegimenDifference (95% CI)3
Clinical Responders at 48 to 72 Hours (ITT)284/349 (81.4)294/349 (84.2)-2.9 (-8.5, 2.8)
Clinical Success at Day 26 to 30 (ITT)295/349 (84.5)297/349 (85.1)-0.6 (-6.0, 4.8)
Clinical Success at Day 26 to 30 (CE)250/271 (92.3)247/267 (92.5)-0.3 (-4.9, 4.4)
1 There were 3 patients in another dalbavancin dosing regimen group who did not receive treatment and were counted as non-responders. 2 Patients who died or used non-study antibacterial therapy or had missing measurements were classified as non-responders. 3 The 95% Confidence Interval (CI) is computed using the Miettinen and Nurminen approach. Abbreviations: ITT-intent to treat; CE-clinically evaluable
","
Table 10. Outcomes by Baseline Pathogen (Trial 3; MicroITT)
Early Clinical Response at 48 to 72 hours
≥ 20% reduction in lesion sizeClinical Success at Day 26 to 30
PathogenSingle dose (1,500 mg) n/N (%)Another Dalbavancin Dosing RegimenSingle dose (1,500 mg) n/N (%)Another Dalbavancin Dosing Regimen
Staphylococcus aureus123/139 (88.5)133/156 (85.3)124/139 (89.2)140/156 (89.7)
Methicillin-susceptible Methicillin-resistant92/103 (89.3)31/36 (86.1)89/96 (89.6)48/61 (78.7)93/103 (90.3)31/36 (86.1)86/96 (89.6)55/61 (90.2)
Streptococcus agalactiae6/6(100.0)4/6 (66.7)5/6 (83.3)5/6 (83.3)
Streptococcus anginosus group31/33 (93.9)19/19 (100.0)29/33 (87.9)17/19 (89.5)
Streptococcus pyogenes14/14 (100.0)18/22 (81.8)13/14 (92.9)19/22 (86.4)
Enterococcus faecalis4/4 (100.0)8/10 (80.0)4/4 (100.0)9/10 (90.0)
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Long-term studies in animals to determine the carcinogenic potential of dalbavancin have not been conducted. Mutagenesis Dalbavancin was not genotoxic in a bacterial reverse mutation (Ames) assay, a mammalian HGPRT gene mutation assay, an in vitro chromosome aberration assay in Chinese Hamster Ovary cells, or an in vivo mouse micronucleus assay. Impairment of Fertility Impaired fertility in the rat was not observed at a dose of 15 mg/kg/day (1.2 times the human dose on an exposure basis). Reductions in male and female fertility and increased embryo resorptions occurred at a dose of 45 mg/kg/day (3.5 times the human dose on an exposure basis), at which signs of parental toxicity were also observed . 13.2 Animal Toxicology and/or Pharmacology Increases in serum levels of liver enzymes (ALT, AST), associated with microscopic findings in the liver were noted in toxicology studies in rats and dogs where dalbavancin was administered daily for 28 to 90 days. Hepatocellular necrosis was observed in dogs dosed at ≥10 mg/kg/day for longer than 2 months, i.e., at approximately 5 to 7 times the expected human dose on an exposure basis. Histiocytic vacuolation and hepatocyte necrosis were observed in rats dosed daily at 40 and 80 mg/kg/day, respectively, for 4 weeks, (approximately 3 and 6 times the expected human dose on an exposure basis, respectively). In addition, renal toxicity characterized by increases in serum BUN and creatinine and microscopic kidney findings was observed in rats and dogs at doses 5 to 7 times the expected human dose on an exposure basis. The relationship between these findings in the animal toxicology studies after 28 and 90 consecutive days of dosing to the indicated clinical dosing of 2 doses 7 days apart are unclear."],"pharmacokinetics_table":["
Table 4. Dalbavancin Pharmacokinetic Parameters in Healthy Subjects
ParameterSingle 1,000 mg DoseSingle 1,500 mg Dose
Cmax (mg/L)287 (13.9)1423 (13.2)4
AUC0-24 (mg•h/L)3,185 (12.8)14,837 (13.7)4
AUC0-Day7 (mg•h/L)11,160 (41.1)2ND
AUC0-inf (mg•h/L)23,443 (40.9)2ND
Terminal t1/2 (h)346 (16.5)2,3ND
CL (L/h)0.0513 (46.8)2ND
All values are presented as mean (% coefficient of variation) 1 Data from 50 healthy subjects. 2 Data from 12 healthy subjects. 3 Based upon population pharmacokinetic analyses of data from patients, the effective half-life is approximately 8.5 days (204 hours). 4 Data from 49 healthy subjects. Abbreviation: ND – not determined
"],"adverse_reactions_table":["
Table 2. Selected Adverse Reactions Occurring in ≥ 2% of Patients Receiving Dalbavancin for Injection in Phase 2/3 Trials (Number (%) of Patients)
Adverse ReactionsDalbavancin for InjectionComparator*
(N = 1,778)(N = 1,224)
Nausea98 (5.5)78 (6.4)
Diarrhea79 (4.4)72 (5.9)
Headache83 (4.7)59 (4.8)
Vomiting50 (2.8)37 (3)
Rash48 (2.7)30 (2.4)
Pruritus38 (2.1)41 (3.3)
* Comparators included linezolid, cefazolin, cephalexin, and vancomycin.
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Allergic Reactions Advise patients that allergic reactions, including serious allergic reactions, could occur with dalbavancin for injection, and that serious allergic reactions require immediate treatment. Patients should inform their healthcare provider about any previous hypersensitivity reactions to dalbavancin for injection, or other glycopeptides [see Warnings and Precautions ( 5.1 )] . Diarrhea Advise patients that diarrhea is a common problem caused by antibacterial drugs, including dalbavancin for injection and usually resolves when the drug is discontinued. Sometimes, frequent watery or bloody diarrhea may occur and may be a sign of a more serious intestinal infection. If severe watery or bloody diarrhea develops, patients should contact their healthcare provider [see Warnings and Precautions ( 5.4 )] . Development of Drug-Resistant Bacteria Patients should be counseled that antibacterial drugs including dalbavancin for injection should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When dalbavancin for injection is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment, and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by dalbavancin for injection or other antibacterial drugs in the future [see Warnings and Precautions ( 5.5 )] . Manufactured In Israel By: Teva Pharmaceutical Ind. Ltd. Kfar Saba, 4410202, Israel Manufactured For: Teva Pharmaceuticals Parsippany, NJ 07054 Iss. 10/2025"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Dosage in Adult Patients ( 2.1 , 2.3 ): Estimated Creatinine Clearance ( C L cr) Single Dose Regimen 30 mL/min and above or on regular hemodialysis 1,500 mg Less than 30 mL/min and not on regular hemodialysis 1,125 mg Administer by intravenous infusion over 30 minutes ( 2.1 , 2.4 ) See Full Prescribing Information for instructions on reconstitution of lyophilized powder and preparation of injection ( 2.4 ) Dosage in Pediatric Patients with CLcr 30 mL/min/1.73m 2 and above ( 2.2 ) Age Range Dosage (Single Dose Regimen) Birth to less than 6 years 22.5 mg/kg (maximum of 1,500 mg) 6 to less than 18 years 18 mg/kg (maximum of 1,500 mg) Dosage adjustment in pediatric patients with CLcr less than 30 mL/min has not been studied. 2.1 Recommended Dos ag e Regimen in Adult Patients with CLcr 30 mL/min and Above The recommended dosage regimen of dalbavancin for injection in adult patients with CLcr 30 mL/min and above is 1,500 mg, administered as a single dose regimen. Administer dalbavancin for injection over 30 minutes by intravenous infusion. For adult patients with CLcr less than 30 mL/min, dosage adjustment is required [see Dosage and Administration ( 2.3 ) and Clinical Pharmacology ( 12.3 ) ] . 2.2 Recommended Dosage Regimen in Pediatric Patients with CLcr 30 mL/min/ 1.73m 2 and Abov e The recommended dosage regimen of dalbavancin for injection in pediatric patients with CLcr 30 mL/min/1.73m 2 and above is a single dose regimen based on the age and weight of the pediatric patient (Table 1). Administer dalbavancin for injection over 30 minutes by intravenous infusion. There is insufficient information to recommend dosage adjustment for pediatric patients younger than 18 years with CLcr less than 30 mL/min/1.73m 2 [see Use in Specific Populations ( 8.4 ) and Clinical Pharmacology ( 12.3 )] . Table 1. Dosage of Dalbavancin for Injection in Pediatric Patients with CLcr* 30 mL/min/1.73m 2 and above Age Range Dosage (Single Dose Regimen) Birth to less than 6 years 22.5 mg/kg (maximum 1,500 mg) 6 to less than 18 years 18 mg/kg (maximum 1,500 mg) *Estimate CLcr or glomerular filtration rate (GFR) using an age-appropriate equation accepted for pediatric patients (birth to less than 18 years old) to define renal function impairment. 2.3 Dosage Adjustments in Adult Patients with CLcr less than 30 mL/min In adult patients with renal impairment whose known CLcr is less than 30 mL/min and who are not receiving regularly scheduled hemodialysis, the recommended dosage regimen of dalbavancin for injection is 1,125 mg, administered as a single dose regimen. No dosage adjustment is recommended for adult patients receiving regularly scheduled hemodialysis, and dalbavancin for injection can be administered without regard to the timing of hemodialysis [see Use in Specific Populations ( 8.6 ) and Clinical Pharmacology ( 12.3 )] . 2.4 Preparation and Administration Dalbavancin for injection must be reconstituted with either Sterile Water for Injection, USP, or 5% Dextrose Injection, USP, and subsequently diluted only with 5% Dextrose Injection, USP, to a final concentration of 1 mg/mL to 5 mg/mL. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Reconstitution: Dalbavancin for injection must be reconstituted under aseptic conditions, using 25 mL of either Sterile Water for Injection, USP, or 5% Dextrose Injection, USP, for each 500 mg vial. To avoid foaming, alternate between gentle swirling and inversion of the vial until its contents are completely dissolved. Do not shake. The reconstituted vial contains 20 mg/mL dalbavancin as a clear, colorless to yellow solution. Reconstituted vials may be stored either refrigerated at 2°C to 8°C (36°F to 46°F), or at controlled room temperature 20°C to 25°C (68°F to 77°F). Do not freeze. Dilution: Adult Patients: Aseptically transfer the required dose of reconstituted dalbavancin for injection solution from the vial(s) to an intravenous bag or bottle containing 5% Dextrose Injection, USP. The diluted solution must have a final dalbavancin concentration of 1 mg/mL to 5 mg/mL. Discard any unused portion of the reconstituted solution. Pediatric Patients: For pediatric patients, the dose of dalbavancin for injection will vary according to the age and weight of the child up to a maximum of 1,500 mg [see Dosage and Administration ( 2.2 )] . Aseptically transfer the required dose of reconstituted dalbavancin for injection solution, based on the child’s weight, from the vial(s) to an intravenous bag or bottle containing 5% Dextrose Injection, USP. The diluted solution must have a final dalbavancin concentration of 1 mg/mL to 5 mg/mL. Discard any unused portion of the reconstituted solution. Once diluted into an intravenous bag or bottle as described above, dalbavancin for injection may be stored either refrigerated at 2°C to 8°C (36°F to 46°F) or at a controlled room temperature of 20°C to 25°C (68°F to 77°F). Do not freeze. The total time from reconstitution to dilution to administration should not exceed 48 hours. Like all parenteral drug products, diluted dalbavancin for injection should be inspected visually for particulate matter prior to infusion. If particulate matter is identified, do not use. Administration : After reconstitution and dilution, administer dalbavancin for injection via intravenous infusion, using a total infusion time of 30 minutes. Do not co-infuse dalbavancin for injection with other medications or electrolytes. Saline-based infusion solutions may cause precipitation and should not be used. The compatibility of reconstituted dalbavancin for injection with intravenous medications, additives, or substances other than 5% Dextrose Injection, USP has not been established. If a common intravenous line is being used to administer other drugs in addition to dalbavancin for injection, the line should be flushed before and after each dalbavancin for injection infusion with 5% Dextrose Injection, USP."],"spl_product_data_elements":["Dalbavancin Dalbavancin DALBAVANCIN HYDROCHLORIDE DALBAVANCIN LACTOSE MONOHYDRATE MANNITOL SODIUM HYDROXIDE HYDROCHLORIC ACID"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Dalbavancin for injection is supplied as a white/off-white to pale yellow lyophilized sterile powder for reconstitution in a single-dose clear glass vial containing dalbavancin hydrochloride equivalent to 500 mg of dalbavancin . For injection: 500 mg of lyophilized powder in a vial for reconstitution ( 3 )"],"clinical_pharmacology_table":["
Table 4. Dalbavancin Pharmacokinetic Parameters in Healthy Subjects
ParameterSingle 1,000 mg DoseSingle 1,500 mg Dose
Cmax (mg/L)287 (13.9)1423 (13.2)4
AUC0-24 (mg•h/L)3,185 (12.8)14,837 (13.7)4
AUC0-Day7 (mg•h/L)11,160 (41.1)2ND
AUC0-inf (mg•h/L)23,443 (40.9)2ND
Terminal t1/2 (h)346 (16.5)2,3ND
CL (L/h)0.0513 (46.8)2ND
All values are presented as mean (% coefficient of variation) 1 Data from 50 healthy subjects. 2 Data from 12 healthy subjects. 3 Based upon population pharmacokinetic analyses of data from patients, the effective half-life is approximately 8.5 days (204 hours). 4 Data from 49 healthy subjects. Abbreviation: ND – not determined
"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies with dalbavancin for injection use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse developmental outcomes. No treatment-related malformations or embryo-fetal toxicity were observed in pregnant rats or rabbits at clinically relevant exposures of dalbavancin. Treatment of pregnant rats with dalbavancin at 3.5 times the human dose on an exposure basis during early embryonic development and from implantation to the end of lactation resulted in delayed fetal maturation and increased fetal loss, respectively [ see Data ] . The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data No evidence of embryo or fetal toxicity was found in the rat or rabbit at a dose of 15 mg/kg/day (1.2 and 0.7 times the human dose on an exposure basis, respectively). Delayed fetal maturation was observed in the rat at a dose of 45 mg/kg/day (3.5 times the human dose on an exposure basis). In a rat prenatal and postnatal development study, increased embryo lethality and increased offspring deaths during the first week post-partum were observed at a dose of 45 mg/kg/day (3.5 times the human dose on an exposure basis). 8.2 Lactation Risk Summary There are no data on the presence of dalbavancin or its metabolite in human milk, the effects on the breast-fed child, or the effects on milk production. Dalbavancin is excreted in the milk of lactating rats. When a drug is present in animal milk, it is likely that the drug will be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for dalbavancin for injection and any potential adverse effects on the breast-fed child from dalbavancin for injection or from the underlying maternal condition. 8.4 Pediatric Use The safety and effectiveness of dalbavancin for injection for the treatment of ABSSSI has been established in pediatric patients aged birth to less than 18 years. Use of dalbavancin for injection for this indication is supported by evidence from adequate and well-controlled studies in adults with additional pharmacokinetic and safety data in pediatric patients aged birth to less than 18 years [see Adverse Reactions ( 6.1 ), Clinical Pharmacology ( 12.3 ), and Clinical Studies (14.1)] . There is insufficient information to recommend dosage adjustment for pediatric patients with ABSSSI and CLcr less than 30 mL/min/1.73m 2 [see Dosage and Administration ( 2.2 )]. 8. 5 Geriatric Use Of the 2,473 patients treated with dalbavancin for injection in Phase 2 and 3 clinical trials, 403 patients (16.3%) were 65 years of age or older. The efficacy and tolerability of dalbavancin for injection were similar to comparator regardless of age. The pharmacokinetics of dalbavancin for injection was not significantly altered with age; therefore, no dosage adjustment is necessary based on age alone. Dalbavancin for injection is substantially excreted by the kidney, and the risk of adverse reactions may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection in this age group. 8.6 Renal Impairment In patients with renal impairment whose known CLcr is less than 30 mL/min and who are not receiving regularly scheduled hemodialysis, the recommended regimen for dalbavancin for injection is 1,125 mg, administered as a single dose. No dosage adjustment is recommended for patients receiving regularly scheduled hemodialysis, and dalbavancin for injection can be administered without regard to the timing of hemodialysis. There is insufficient information to recommend dosage adjustment for pediatric patients younger than 18 years with CLcr less than 30 mL/min/1.73m 2 [see Dosage and Administration ( 2.3 ) , Clinical Pharmacology ( 12.3 )] . 8.7 Hepatic Impairment No dosage adjustment of dalbavancin for injection is recommended for patients with mild hepatic impairment (Child-Pugh Class A). Caution should be exercised when prescribing dalbavancin for injection to patients with moderate or severe hepatic impairment (Child-Pugh Class B or C) as no data are available to determine the appropriate dosing in these patients [ see Clinical Pharmacology ( 12.3 ) ] ."],"dosage_and_administration_table":["
Dosage in Adult Patients (2.1, 2.3):
Estimated Creatinine Clearance (CLcr)Single Dose Regimen
30 mL/min and above or on regular hemodialysis1,500 mg
Less than 30 mL/min and not on regular hemodialysis1,125 mg
","
Dosage in Pediatric Patients with CLcr 30 mL/min/1.73m2 and above (2.2)
Age RangeDosage (Single Dose Regimen)
Birth to less than 6 years22.5 mg/kg (maximum of 1,500 mg)
6 to less than 18 years18 mg/kg (maximum of 1,500 mg)
","
Table 1. Dosage of Dalbavancin for Injection in Pediatric Patients with CLcr* 30 mL/min/1.73m2 and above
Age RangeDosage (Single Dose Regimen)
Birth to less than 6 years22.5 mg/kg (maximum 1,500 mg)
6 to less than 18 years 18 mg/kg (maximum 1,500 mg)
*Estimate CLcr or glomerular filtration rate (GFR) using an age-appropriate equation accepted for pediatric patients (birth to less than 18 years old) to define renal function impairment.
"],"animal_pharmacology_and_or_toxicology":["13.2 Animal Toxicology and/or Pharmacology Increases in serum levels of liver enzymes (ALT, AST), associated with microscopic findings in the liver were noted in toxicology studies in rats and dogs where dalbavancin was administered daily for 28 to 90 days. Hepatocellular necrosis was observed in dogs dosed at ≥10 mg/kg/day for longer than 2 months, i.e., at approximately 5 to 7 times the expected human dose on an exposure basis. Histiocytic vacuolation and hepatocyte necrosis were observed in rats dosed daily at 40 and 80 mg/kg/day, respectively, for 4 weeks, (approximately 3 and 6 times the expected human dose on an exposure basis, respectively). In addition, renal toxicity characterized by increases in serum BUN and creatinine and microscopic kidney findings was observed in rats and dogs at doses 5 to 7 times the expected human dose on an exposure basis. The relationship between these findings in the animal toxicology studies after 28 and 90 consecutive days of dosing to the indicated clinical dosing of 2 doses 7 days apart are unclear."],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL NDC 0480-3325-01 Dalbavancin for Injection 500 mg per vial For Intravenous Infusion Only Sterile Single-Dose Vial Discard Unused Portion Rx only One Vial carton"],"drug_and_or_laboratory_test_interactions":["7.1 Drug-Laboratory Test Interactions Drug-laboratory test interactions have not been reported. Dalbavancin for injection at therapeutic concentrations does not artificially prolong prothrombin time (PT) or activated partial thromboplastin time (aPTT)."],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Long-term studies in animals to determine the carcinogenic potential of dalbavancin have not been conducted. Mutagenesis Dalbavancin was not genotoxic in a bacterial reverse mutation (Ames) assay, a mammalian HGPRT gene mutation assay, an in vitro chromosome aberration assay in Chinese Hamster Ovary cells, or an in vivo mouse micronucleus assay. Impairment of Fertility Impaired fertility in the rat was not observed at a dose of 15 mg/kg/day (1.2 times the human dose on an exposure basis). Reductions in male and female fertility and increased embryo resorptions occurred at a dose of 45 mg/kg/day (3.5 times the human dose on an exposure basis), at which signs of parental toxicity were also observed ."]},"tags":[{"label":"Lipoglycopeptide Antibacterial","category":"class"},{"label":"Peptide","category":"modality"},{"label":"J01XA04","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Injection","category":"form"},{"label":"Generic Available","category":"availability"},{"label":"LOE Approaching","category":"status"},{"label":"Bacterial infection of skin","category":"indication"},{"label":"Infection of skin AND/OR subcutaneous tissue","category":"indication"},{"label":"Staphylococcal infection of skin","category":"indication"},{"label":"Abbvie","category":"company"},{"label":"Approved 2010s","category":"decade"},{"label":"Anti-Bacterial Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"161 reports"},{"date":"","signal":"RASH","source":"FDA FAERS","actionTaken":"98 reports"},{"date":"","signal":"PRURITUS","source":"FDA FAERS","actionTaken":"60 reports"},{"date":"","signal":"BACK PAIN","source":"FDA FAERS","actionTaken":"58 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"58 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"55 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"54 reports"},{"date":"","signal":"ERYTHEMA","source":"FDA FAERS","actionTaken":"50 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"49 reports"},{"date":"","signal":"HYPERSENSITIVITY","source":"FDA FAERS","actionTaken":"47 reports"}],"commonSideEffects":[{"effect":"Nausea","drugRate":"5.5%","severity":"common","_validated":true},{"effect":"Headache","drugRate":"4.7%","severity":"common","_validated":true},{"effect":"Diarrhea","drugRate":"4.4%","severity":"common","_validated":true},{"effect":"Vomiting","drugRate":"2.8%","severity":"mild","_validated":true},{"effect":"Rash","drugRate":"2.7%","severity":"mild","_validated":true},{"effect":"Pruritus","drugRate":"2.1%","severity":"mild","_validated":true},{"effect":"Pyrexia","drugRate":"reported","severity":"unknown"},{"effect":"Anemia","drugRate":"reported","severity":"unknown"},{"effect":"Leucopenia","drugRate":"reported","severity":"unknown"},{"effect":"Neutropenia","drugRate":"reported","severity":"unknown"},{"effect":"Thrombocytopenia","drugRate":"reported","severity":"unknown"},{"effect":"Petechiae","drugRate":"reported","severity":"unknown"},{"effect":"Eosinophilia","drugRate":"reported","severity":"unknown"},{"effect":"Thrombocytosis","drugRate":"reported","severity":"unknown"},{"effect":"Gastrointestinal hemorrhage","drugRate":"reported","severity":"unknown"},{"effect":"Melena","drugRate":"reported","severity":"unknown"},{"effect":"Hematochezia","drugRate":"reported","severity":"unknown"},{"effect":"Abdominal pain","drugRate":"reported","severity":"unknown"},{"effect":"Infusion-related reactions","drugRate":"reported","severity":"unknown"},{"effect":"Hepatotoxicity","drugRate":"reported","severity":"unknown"},{"effect":"Anaphylactic reaction","drugRate":"reported","severity":"unknown"},{"effect":"Clostridioides difficile colitis","drugRate":"reported","severity":"unknown"},{"effect":"Oral candidiasis","drugRate":"reported","severity":"unknown"},{"effect":"Vulvovaginal mycotic infection","drugRate":"reported","severity":"unknown"},{"effect":"Hepatic transaminases increased","drugRate":"reported","severity":"unknown"},{"effect":"Blood alkaline phosphatase increased","drugRate":"reported","severity":"unknown"},{"effect":"International normalized ratio increased","drugRate":"reported","severity":"unknown"},{"effect":"Blood lactate dehydrogenase increased","drugRate":"reported","severity":"unknown"},{"effect":"Gamma-glutamyl transferase increased","drugRate":"reported","severity":"unknown"}],"specialPopulations":{"Pregnancy":"There are no adequate and well-controlled studies with DALVANCE use in pregnant women to evaluate for drug-associated risk of major birth defects, miscarriage or adverse developmental outcomes. No treatment-related malformations or embryo-fetal toxicity were observed in pregnant rats or rabbits at clinically relevant exposures of dalbavancin. Treatment of pregnant rats with dalbavancin at 3.5 times the human dose on an exposure basis during early embryonic development and from implantation to the end of lactation resulted in delayed fetal maturation and increased fetal loss, respectively. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.","Geriatric use":"Of the 2473 patients treated with DALVANCE in Phase and clinical trials, 403 patients (16.3%) were 65 years of age or older. The efficacy and tolerability of DALVANCE were similar to comparator regardless of age. The pharmacokinetics of DALVANCE was not significantly altered with age; therefore, no dosage adjustment is necessary based on age alone. DALVANCE is substantially excreted by the kidney, and the risk of adverse reactions may be greater in patients with impaired renal function.","Paediatric use":"The safety and effectiveness of DALVANCE for the treatment of ABSSSI has been established in pediatric patients aged birth to less than 18 years. Use of DALVANCE for this indication is supported by evidence from adequate and well-controlled studies in adults with additional pharmacokinetic and safety data in pediatric patients aged birth to less than 18 years. There is insufficient information to recommend the use of DALVANCE in pediatric patients less than 1 year of age.","Renal impairment":"DALVANCE is substantially excreted by the kidney, and the risk of adverse reactions may be greater in patients with impaired renal function."}},"trials":[],"aliases":[],"company":"AbbVie","patents":[{"applNo":"N021883","source":"FDA Orange Book","status":"Active","expires":"May 23, 2028","useCode":"U-3499","territory":"US","drugProduct":false,"patentNumber":"6900175","drugSubstance":false}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=DALBAVANCIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:07:39.954226+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:07:38.054198+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:07:46.089240+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T00:07:39.971479+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:07:36.649136+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DALBAVANCIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:07:46.882400+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:07:35.499748+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:07:35.499787+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:07:48.377481+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3301669/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:07:47.370511+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA219465","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:07:35.499793+00:00"}},"allNames":"dalvance","offLabel":[],"synonyms":["xydalba","dalvance","dalbavancin","dalbavancin hydrochloride","BI397","MDL 63,397","VER001","dalbavancin HCl"],"timeline":[{"date":"2014-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from DURATA THERAPS INTL to Abbvie"},{"date":"2014-05-23","type":"positive","source":"DrugCentral","milestone":"FDA approval (Durata Theraps Intl)"},{"date":"2014-12-18","type":"positive","source":"DrugCentral","milestone":"EMA approval"},{"date":"2026-02-26","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 4 manufacturers approved"}],"approvals":[{"date":"2014-05-23","orphan":false,"company":"DURATA THERAPS INTL","regulator":"FDA"},{"date":"2014-12-18","orphan":false,"company":"","regulator":"EMA"}],"brandName":"Dalvance","ecosystem":[{"indication":"Bacterial infection of skin","otherDrugs":[{"name":"chloramphenicol","slug":"chloramphenicol","company":"Parkedale"},{"name":"delafloxacin","slug":"delafloxacin","company":"Melinta Therapeutics Inc"},{"name":"gentamicin","slug":"gentamicin","company":"Schering"},{"name":"omadacycline","slug":"omadacycline","company":"Paratek Pharms Inc"}],"globalPrevalence":null},{"indication":"Infection of skin AND/OR subcutaneous tissue","otherDrugs":[{"name":"alatrofloxacin","slug":"alatrofloxacin","company":"Pfizer"},{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"amphotericin B","slug":"amphotericin-b","company":"Apothecon"}],"globalPrevalence":null},{"indication":"Staphylococcal infection of skin","otherDrugs":[{"name":"oritavancin","slug":"oritavancin","company":"The Medicines Co"},{"name":"ozenoxacin","slug":"ozenoxacin","company":"Ferrer Internacional S.A."},{"name":"tedizolid phosphate","slug":"tedizolid-phosphate","company":"Cubist Pharms Inc"}],"globalPrevalence":null}],"mechanism":{"novelty":"Follow-on","modality":"Small Molecule","drugClass":"Lipoglycopeptide Antibacterial","explanation":"Dalbavancin is an antibacterial drug [see Microbiology 12.4 )].","oneSentence":"Dalvance works by binding to the bacterial cell wall, disrupting its synthesis and ultimately leading to cell death.","technicalDetail":"Dalvance exerts its antibacterial activity by inhibiting cell wall synthesis through the binding of its lipoglycopeptide moiety to the bacterial cell wall, specifically targeting the D-alanyl-D-alanine (D-Ala-D-Ala) terminus of the bacterial cell wall precursors."},"commercial":{"launchDate":"2014","revenueYear":2025,"_launchSource":"DrugCentral (FDA 2014-05-23, DURATA THERAPS INTL)","annualRevenue":260,"revenueSource":"Teva 2026-02-03 (verified from SEC filing)","revenueCurrency":"USD","revenueConfidence":"high"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/777","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=DALBAVANCIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DALBAVANCIN","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T10:23:39.162557","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:07:53.552642+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"vancomycin","drugSlug":"vancomycin","fdaApproval":"1964-11-06","patentExpiry":"Nov 6, 2035","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"telavancin","drugSlug":"telavancin","fdaApproval":"2009-09-11","patentExpiry":"Jan 1, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"oritavancin","drugSlug":"oritavancin","fdaApproval":"2014-08-06","patentExpiry":"Jul 16, 2035","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"dalbavancin","indications":{"approved":[{"name":"Bacterial infection of skin","source":"DrugCentral","snomedId":128936008,"regulator":"FDA"},{"name":"Infection of skin AND/OR subcutaneous tissue","source":"DrugCentral","snomedId":19824006,"regulator":"FDA"},{"name":"Staphylococcal infection of skin","source":"DrugCentral","snomedId":402938009,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"currentOwner":"Abbvie","drugCategory":"loe-approaching","labelChanges":[],"relatedDrugs":[{"drugId":"vancomycin","brandName":"vancomycin","genericName":"vancomycin","approvalYear":"1964","relationship":"same-class"},{"drugId":"telavancin","brandName":"telavancin","genericName":"telavancin","approvalYear":"2009","relationship":"same-class"},{"drugId":"oritavancin","brandName":"oritavancin","genericName":"oritavancin","approvalYear":"2014","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06810583","phase":"PHASE1","title":"A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2025-05-22","conditions":["Leukemia","Acute Myeloid Leukemia","Lymphoblastic Leukemia in Children"],"enrollment":29,"completionDate":"2031-09"},{"nctId":"NCT06688084","phase":"","title":"Pathogenicity Factors of Staphylococcus Pettenkoferi in Foot Wounds and Osteitis in Diabetic Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2024-01-01","conditions":["Diabetic Foot Ulcer"],"enrollment":230,"completionDate":"2026-05-01"},{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":["Endovascular Infection","Bone and Joint Infection","Skin and Soft Tissue Infection","Pulmonary Infection","Gastrointestinal Infection","Genitourinary Infection"],"enrollment":94,"completionDate":"2025-02-14"},{"nctId":"NCT06423898","phase":"PHASE4","title":"Ampicillin and Ceftriaxone for the Treatment of Enterococcus Faecalis Infective Endocarditis.","status":"RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2024-10-09","conditions":["Endocarditis, Infective"],"enrollment":284,"completionDate":"2028-12-31"},{"nctId":"NCT05117398","phase":"PHASE3","title":"Dalbavancin Versus Standard Antibiotic Therapy for Catheter-related Bloodstream Infections Due to Staphylococcus Aureus","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-06-23","conditions":["Catheter Bacteremia","Staphylococcus Aureus Infection"],"enrollment":406,"completionDate":"2026-09-23"},{"nctId":"NCT06899906","phase":"","title":"Efficacy and Safety of Dalbavancin As Suppressive Therapy","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2024-10-01","conditions":["Efficacy and Safety of Dalbavancin","In Subjects Who Received SAT with DAL","For Acute or Chronic Infections Between July 2019 and December 2024"],"enrollment":33,"completionDate":"2025-05-01"},{"nctId":"NCT04775953","phase":"PHASE2","title":"DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-22","conditions":["Staphylococcal Bacteraemia"],"enrollment":200,"completionDate":"2023-12-01"},{"nctId":"NCT02814916","phase":"PHASE3","title":"Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA","status":"COMPLETED","sponsor":"AbbVie","isPivotal":true,"startDate":"2017-03-30","conditions":["Methicillin-Resistant Staphylococcus Aureus","Bacterial Infections","Staphylococcal Skin Infections"],"enrollment":199,"completionDate":"2024-01-01"},{"nctId":"NCT06266494","phase":"PHASE4","title":"Prevention and Treatment of Frostbite Infection With Antimicrobial Pharmacokinetic Analysis","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2024-03-01","conditions":["Frostbite"],"enrollment":100,"completionDate":"2026-08"},{"nctId":"NCT04624451","phase":"","title":"Evaluation of Intravenous Dalbavancin for Peritonitis","status":"TERMINATED","sponsor":"University of Colorado, Denver","startDate":"2020-06-01","conditions":["Peritonitis","Peritonitis Bacterial"],"enrollment":2,"completionDate":"2024-01-31"},{"nctId":"NCT05046860","phase":"NA","title":"Efficacy of Dalbavancin in Osteoarticular Infections Associated With Hip and Knee Replacements","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2022-03-07","conditions":["Osteoarticular Infection"],"enrollment":43,"completionDate":"2024-09-30"},{"nctId":"NCT04847921","phase":"PHASE2,PHASE3","title":"Substance Use Disorder (SUD)-Associated Infections' Treatment With Dalbavancin ENabling OUtpatient Transition","status":"TERMINATED","sponsor":"University of Colorado, Denver","startDate":"2021-04-30","conditions":["Gram-Positive Bacterial Infections","Gram-Positive Bacteraemia","Substance Use Disorders","Intravenous Substance Abuse"],"enrollment":11,"completionDate":"2023-10-05"},{"nctId":"NCT06089044","phase":"","title":"Evaluation of the Efficacy and Safety of Suppressive Therapy With DALBAVANCINE in Device Infections","status":"COMPLETED","sponsor":"Tourcoing Hospital","startDate":"2020-01-01","conditions":["Prosthesis-related Infections"],"enrollment":15,"completionDate":"2022-12-31"},{"nctId":"NCT03426761","phase":"PHASE4","title":"Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections","status":"COMPLETED","sponsor":"Infectious Diseases Physicians, Inc.","startDate":"2018-01-25","conditions":["Bone Infection","Osteomyelitis","Septic Arthritis","Joint Infection","Prosthetic Joint Infection"],"enrollment":41,"completionDate":"2022-12-31"},{"nctId":"NCT03982030","phase":"PHASE4","title":"Dalbavancin Outpatient Pilot","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2023-04","conditions":["Gram-Positive Bacterial Infections","Soft Tissue Infections"],"enrollment":0,"completionDate":"2025-07"},{"nctId":"NCT03372941","phase":"PHASE4","title":"Hospital Avoidance Strategies for ABSSSI","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2019-03-04","conditions":["Skin Infection"],"enrollment":11,"completionDate":"2021-10-14"},{"nctId":"NCT04959799","phase":"","title":"Dalbavancin Real-life Utilization in Diabetic Patients Suffering From Infections (DALBADIA)","status":"COMPLETED","sponsor":"Aziende Chimiche Riunite Angelini Francesco S.p.A","startDate":"2022-01-02","conditions":["Diabetes","Infection"],"enrollment":98,"completionDate":"2022-05-31"},{"nctId":"NCT04485676","phase":"","title":"Dalbavancin in Real Clinical Practice in Spain","status":"COMPLETED","sponsor":"Angelini Farmacéutica","startDate":"2020-07-15","conditions":["Skin Diseases, Bacterial","Skin Diseases, Infectious"],"enrollment":187,"completionDate":"2021-02-21"},{"nctId":"NCT03148756","phase":"PHASE2","title":"Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis","status":"TERMINATED","sponsor":"AbbVie","startDate":"2017-05-12","conditions":["Endocarditis","Bacteremia"],"enrollment":2,"completionDate":"2017-08-04"},{"nctId":"NCT02688790","phase":"PHASE1","title":"Study Evaluate the PK Profile of Dalbavancin in Infants and Neonates Patients With Known or Suspected Bacterial Infection","status":"TERMINATED","sponsor":"AbbVie","startDate":"2016-04-01","conditions":["Bacterial Infections"],"enrollment":8,"completionDate":"2019-04-03"},{"nctId":"NCT04298463","phase":"","title":"Retrospective Effectiveness Study of Dalbavancin and Other Standard of Care of the Same Class in Patients With ABSSSI","status":"COMPLETED","sponsor":"Aziende Chimiche Riunite Angelini Francesco S.p.A","startDate":"2020-06-18","conditions":["Acute Bacterial Skin and Skin Structure Infection"],"enrollment":184,"completionDate":"2021-05-19"},{"nctId":"NCT03726216","phase":"","title":"Xydalba Utilization Registry in France","status":"COMPLETED","sponsor":"Correvio International Sarl","startDate":"2018-09-06","conditions":["Bacterial Infections"],"enrollment":151,"completionDate":"2020-10-28"},{"nctId":"NCT02940730","phase":"PHASE4","title":"Evaluation of Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2017-05-01","conditions":["Infectious Peritonitis"],"enrollment":10,"completionDate":"2018-06-18"},{"nctId":"NCT03696901","phase":"","title":"Xydalba Utilization Registry in Germany","status":"TERMINATED","sponsor":"Correvio International Sarl","startDate":"2018-11-21","conditions":["Bacterial Infections"],"enrollment":16,"completionDate":"2020-04-07"},{"nctId":"NCT03941951","phase":"NA","title":"Study to Optimize the Use of New Antibiotics","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2019-07-09","conditions":["Bacterial Infections","Fungal Infection"],"enrollment":900,"completionDate":"2022-12-31"},{"nctId":"NCT02961764","phase":"PHASE4","title":"Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)","status":"COMPLETED","sponsor":"Allergan","startDate":"2016-11-29","conditions":["Acute Bacterial Skin and Skin Structure Infections"],"enrollment":313,"completionDate":"2019-03-29"},{"nctId":"NCT03233438","phase":"PHASE4","title":"Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)","status":"COMPLETED","sponsor":"Allergan","startDate":"2017-07-24","conditions":["Bacterial Infections","Acute Bacterial Skin and Skin Structure Infection"],"enrollment":91,"completionDate":"2018-10-30"},{"nctId":"NCT02685033","phase":"PHASE2","title":"Study on the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Participants With Osteomyelitis","status":"COMPLETED","sponsor":"Durata Therapeutics Inc., an affiliate of Allergan plc","startDate":"2016-03-15","conditions":["Osteomyelitis"],"enrollment":80,"completionDate":"2017-12-12"},{"nctId":"NCT02127970","phase":"PHASE3","title":"Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections","status":"COMPLETED","sponsor":"Durata Therapeutics Inc., an affiliate of Allergan plc","startDate":"2014-04-18","conditions":["Abscess","Wound Infection","Surgical Site Infection","Cellulitis"],"enrollment":698,"completionDate":"2015-03-11"},{"nctId":"NCT03091439","phase":"PHASE2","title":"Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis","status":"TERMINATED","sponsor":"Allergan","startDate":"2017-05-15","conditions":["Osteomyelitis"],"enrollment":1,"completionDate":"2017-08-31"},{"nctId":"NCT02344511","phase":"PHASE3","title":"Dalbavancin vs Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis","status":"WITHDRAWN","sponsor":"Durata Therapeutics International BV (an Affiliate of Actavis, Inc.)","startDate":"2016-03","conditions":["Osteomyelitis"],"enrollment":0,"completionDate":"2019-04"},{"nctId":"NCT02269644","phase":"PHASE3","title":"A P3 Comparator Trial in Community Acquired Bacterial Pneumonia","status":"WITHDRAWN","sponsor":"Durata Therapeutics Inc., an affiliate of Allergan plc","startDate":"2015-11","conditions":["Community Acquired Pneumonia"],"enrollment":0,"completionDate":"2016-12"},{"nctId":"NCT01946568","phase":"PHASE1","title":"A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.","status":"COMPLETED","sponsor":"Durata Therapeutics Inc., an affiliate of Allergan plc","startDate":"2013-06","conditions":["Bacterial Infections."],"enrollment":36,"completionDate":"2015-04"},{"nctId":"NCT01431339","phase":"PHASE3","title":"Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections","status":"COMPLETED","sponsor":"Durata Therapeutics Inc., an affiliate of Allergan plc","startDate":"2011-07","conditions":["Abscess","Wound Infection","Surgical Site Infection","Cellulitis"],"enrollment":739,"completionDate":"2012-12"},{"nctId":"NCT01339091","phase":"PHASE3","title":"Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections","status":"COMPLETED","sponsor":"Durata Therapeutics Inc., an affiliate of Allergan plc","startDate":"2011-03","conditions":["Abscess","Wound Infection","Surgical Site Infection","Cellulitis"],"enrollment":573,"completionDate":"2012-11"},{"nctId":"NCT00678106","phase":"PHASE1","title":"Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-09","conditions":["Bacterial Infections"],"enrollment":10,"completionDate":"2009-07"},{"nctId":"NCT00057369","phase":"PHASE2","title":"Safety and Efficacy of Dalbavancin Versus Vancomycin in the Treatment of Catheter-Related Bloodstream Infections","status":"UNKNOWN","sponsor":"Vicuron Pharmaceuticals","startDate":"2001-02","conditions":["Bacteremia"],"enrollment":88,"completionDate":"2003-06"}],"_emaApprovals":[{"date":"2014-12-18","status":"Authorised","company":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"pivotalTrials":["NCT02814916"],"administration":{"route":"Intravenous","formulation":"Injection","formulations":[{"form":"INJECTION, POWDER, FOR SOLUTION","route":"INTRAVENOUS","productName":"DALVANCE"}]},"_patentsChecked":true,"crossReferences":{"MMSL":"221316","NDDF":"015537","UNII":"808UI9MS5K","CHEBI":"CHEBI:82721","VANDF":"4025243","INN_ID":"7978","RXNORM":"1539239","UMLSCUI":"C1172636","chemblId":"CHEMBL3301669","ChEMBL_ID":"CHEMBL3301669","KEGG_DRUG":"D03640","DRUGBANK_ID":"DB06219","PUBCHEM_CID":"16134627","SNOMEDCT_US":"703917001","IUPHAR_LIGAND_ID":"10876","MESH_SUPPLEMENTAL_RECORD_UI":"C469289"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2014-","companyName":"Durata Theraps Intl","relationship":"Original Developer"},{"period":"present","companyName":"Abbvie","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"170.0 hours","clearance":"0.01 mL/min/kg","fractionUnbound":"0.02%","volumeOfDistribution":"0.14 L/kg"},"publicationCount":850,"therapeuticAreas":["Infectious Disease"],"_revenueScrapedAt":"2026-03-31 14:09:34.431478+00","atcClassification":{"source":"DrugCentral","atcCode":"J01XA04","allCodes":["J01XA04"]},"biosimilarFilings":[],"originalDeveloper":"Durata Theraps Intl","recentPublications":[{"date":"2026 Mar 1","pmid":"41892415","title":"Proactive Therapeutic Drug Monitoring of Dalbavancin in the Long-Term Treatment of Chronic Infections: A Narrative Review.","journal":"Antibiotics (Basel, Switzerland)"},{"date":"2026 Mar 15","pmid":"41839500","title":"Dalbavancin.","journal":"CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne"},{"date":"2026 Feb 4","pmid":"41832131","title":"[Persistent headache after dalbavancine infusion: About one case].","journal":"Therapie"},{"date":"2026 Mar","pmid":"41822371","title":"Emergence of Dalbavancin, Vancomycin, and Daptomycin Cross-resistance in MRSA During Long-term LVAD Suppression With Vancomycin Followed by Dalbavancin: Genomic Insights and Synergy With Cefadroxil.","journal":"Open forum infectious diseases"},{"date":"2026 Mar 12","pmid":"41820727","title":"Corallopyronin A exhibits potent activity against staphylococci including MRSA and isolates from prosthetic infections.","journal":"Infection"}],"companionDiagnostics":[],"genericManufacturers":4,"_genericFilersChecked":true,"genericManufacturerList":["Fresenius Kabi Usa","Kindos","Long Grove Pharms","Teva Pharms Inc"],"status":"approved","companyName":"Abbvie","companyId":"abbvie","modality":"Recombinant protein","firstApprovalDate":"2014","aiSummary":"","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2014-05-23T00:00:00.000Z","mah":"DURATA THERAPS INTL","brand_name_local":null,"application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"2014-05-23T00:00:00.000Z","mah":"DURATA THERAPS INTL","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"2014-05-23T00:00:00.000Z","mah":"DURATA THERAPS INTL","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"2014-05-23T00:00:00.000Z","mah":"DURATA THERAPS INTL","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"2014-05-23T00:00:00.000Z","mah":"DURATA THERAPS INTL","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"2014-05-23T00:00:00.000Z","mah":"DURATA THERAPS INTL","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2015-12-18T00:00:00.000Z","mah":"ABBVIE","brand_name_local":null,"application_number":"NDA021883"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-10-23T00:00:00.000Z","mah":"TEVA PHARMS INC","brand_name_local":null,"application_number":"ANDA219465"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-11-10T00:00:00.000Z","mah":"FRESENIUS KABI USA","brand_name_local":null,"application_number":"ANDA217591"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-11-26T00:00:00.000Z","mah":"KINDOS","brand_name_local":null,"application_number":"ANDA218929"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2026-02-26T00:00:00.000Z","mah":"LONG GROVE PHARMS","brand_name_local":null,"application_number":"ANDA218602"},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:07:53.552642+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}